SENATE 476118th CongressSubmitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S5642; text: CR S5641)

A resolution supporting the goals and ideals of a National Move Over Law Day.

Last Action: 11/28/2023

Actions

2023-02-16Read twice and referred to the Committee on Finance.
2023-02-16Introduced in Senate

CRS Summary

As of 2023-02-16 (00)

Maintaining Investments in New Innovation Act

This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Cosponsors (3)

Marsha Blackburn (R-TN)
Ted Budd (R-NC)
Steve Daines (R-MT)

Subjects

Genetics
Medicare
Prescription drugs

Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.